Boston Scientific Co. (NYSE:BSX) Shares Sold by Westover Capital Advisors LLC

Westover Capital Advisors LLC cut its holdings in shares of Boston Scientific Co. (NYSE:BSX) by 1.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 15,432 shares of the medical equipment provider’s stock after selling 231 shares during the period. Westover Capital Advisors LLC’s holdings in Boston Scientific were worth $892,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of BSX. Victory Capital Management Inc. increased its stake in Boston Scientific by 5.6% in the 3rd quarter. Victory Capital Management Inc. now owns 518,047 shares of the medical equipment provider’s stock valued at $27,353,000 after purchasing an additional 27,620 shares in the last quarter. Louisiana State Employees Retirement System purchased a new stake in shares of Boston Scientific in the 4th quarter worth about $5,116,000. Glenmede Trust Co. NA increased its holdings in Boston Scientific by 12.1% during the 3rd quarter. Glenmede Trust Co. NA now owns 10,442 shares of the medical equipment provider’s stock valued at $551,000 after acquiring an additional 1,123 shares in the last quarter. Principal Financial Group Inc. lifted its holdings in shares of Boston Scientific by 2.1% in the third quarter. Principal Financial Group Inc. now owns 1,868,991 shares of the medical equipment provider’s stock valued at $98,683,000 after purchasing an additional 38,249 shares in the last quarter. Finally, HealthInvest Partners AB purchased a new position in shares of Boston Scientific during the 4th quarter worth approximately $3,746,000. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Boston Scientific Stock Down 0.3 %

BSX traded down $0.23 during trading hours on Thursday, reaching $71.98. 4,779,494 shares of the stock traded hands, compared to its average volume of 6,616,699. Boston Scientific Co. has a fifty-two week low of $48.35 and a fifty-two week high of $74.39. The company has a market cap of $107.97 billion, a price-to-earnings ratio of 60.68, a PEG ratio of 2.47 and a beta of 0.77. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.32 and a quick ratio of 0.82. The firm’s fifty day simple moving average is $68.20 and its two-hundred day simple moving average is $61.03.

Boston Scientific (NYSE:BSX) last announced its earnings results on Wednesday, January 31st. The medical equipment provider reported $0.55 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.51 by $0.04. Boston Scientific had a return on equity of 16.63% and a net margin of 12.06%. The business had revenue of $3.73 billion for the quarter, compared to analyst estimates of $3.59 billion. During the same period in the previous year, the company earned $0.45 earnings per share. As a group, analysts forecast that Boston Scientific Co. will post 2.32 earnings per share for the current fiscal year.

Insider Buying and Selling at Boston Scientific

In related news, Director Edward J. Ludwig sold 7,000 shares of Boston Scientific stock in a transaction on Tuesday, February 13th. The shares were sold at an average price of $65.03, for a total value of $455,210.00. Following the completion of the sale, the director now owns 41,374 shares in the company, valued at $2,690,551.22. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In other news, Director Edward J. Ludwig sold 7,000 shares of Boston Scientific stock in a transaction that occurred on Tuesday, February 13th. The stock was sold at an average price of $65.03, for a total value of $455,210.00. Following the completion of the transaction, the director now owns 41,374 shares in the company, valued at approximately $2,690,551.22. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Wendy Carruthers sold 6,983 shares of the firm’s stock in a transaction on Friday, February 23rd. The stock was sold at an average price of $66.89, for a total value of $467,092.87. Following the transaction, the executive vice president now owns 56,508 shares in the company, valued at $3,779,820.12. The disclosure for this sale can be found here. Insiders have sold a total of 60,797 shares of company stock valued at $4,138,090 in the last three months. Corporate insiders own 0.50% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have commented on BSX. Mizuho increased their target price on Boston Scientific from $80.00 to $85.00 and gave the company a “buy” rating in a report on Thursday, April 25th. TD Cowen boosted their target price on shares of Boston Scientific from $65.00 to $77.00 and gave the company an “outperform” rating in a research note on Thursday, March 7th. Barclays raised their price target on shares of Boston Scientific from $70.00 to $78.00 and gave the stock an “overweight” rating in a research note on Friday, April 26th. Needham & Company LLC upped their price objective on shares of Boston Scientific from $71.00 to $82.00 and gave the company a “buy” rating in a research note on Wednesday, April 24th. Finally, Oppenheimer lifted their target price on shares of Boston Scientific from $58.00 to $68.00 and gave the stock a “market perform” rating in a research note on Thursday, February 1st. Three equities research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $75.09.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.